448 related articles for article (PubMed ID: 11536225)
21. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.
Bakhouch K; Oulad-Lahcen A; Bensghir R; Blaghen M; Elfilali KM; Ezzikouri S; Abidi O; Hassar M; Wakrim L
J Infect Dev Ctries; 2009 Jun; 3(5):380-91. PubMed ID: 19759509
[TBL] [Abstract][Full Text] [Related]
22. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1.
Handema R; Terunuma H; Kasolo F; Kasai H; Sichone M; Yamashita A; Deng X; Mulundu G; Ichiyama K; Munkanta M; Yokota T; Wakasugi N; Tezuka F; Yamamoto N; Ito M
AIDS Res Hum Retroviruses; 2003 Feb; 19(2):151-60. PubMed ID: 12643279
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
26. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 drug resistance in newly infected individuals.
Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
30. Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy.
Verhofstede C; Noë A; Demecheleer E; De Cabooter N; Van Wanzeele F; Van Der Gucht B; Vogelaers D; Plum J
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):473-83. PubMed ID: 15021312
[TBL] [Abstract][Full Text] [Related]
31. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
[TBL] [Abstract][Full Text] [Related]
32. Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report.
Quan Y; Brenner BG; Dascal A; Wainberg MA
Retrovirology; 2008 May; 5():43. PubMed ID: 18513421
[TBL] [Abstract][Full Text] [Related]
33. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART.
Wang YM; Dyer WB; Workman C; Wang B; Sullivan JS; Saksena NK
AIDS; 2000 Oct; 14(15):2265-72. PubMed ID: 11089614
[TBL] [Abstract][Full Text] [Related]
34. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART.
Wang YM; Dyer WB; Workman C; Wang B; Peng NK; Lachireddy K; Chew CB; Sullivan J; Saksena NK
Curr HIV Res; 2007 Mar; 5(2):235-50. PubMed ID: 17346137
[TBL] [Abstract][Full Text] [Related]
35. Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.
Sarmati L; Nicastri E; Uccella I; D'Ettorre G; Parisi SG; Palmisano L; Galluzzo C; Concia E; Vullo V; Vella S; Andreoni M
J Clin Microbiol; 2003 Apr; 41(4):1760-2. PubMed ID: 12682180
[TBL] [Abstract][Full Text] [Related]
36. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
[TBL] [Abstract][Full Text] [Related]
37. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid.
Cinque P; Presi S; Bestetti A; Pierotti C; Racca S; Boeri E; Morelli P; Carrera P; Ferrari M; Lazzarin A
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):377-83. PubMed ID: 11282006
[TBL] [Abstract][Full Text] [Related]
38. Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.
Santoro MM; Ciccozzi M; Alteri C; Montieri S; Alexiev I; Dimova I; Ceccherini-Silberstein F; Beshkov D; Rezza G; Perno CF
AIDS Res Hum Retroviruses; 2008 Sep; 24(9):1133-8. PubMed ID: 18788909
[TBL] [Abstract][Full Text] [Related]
39. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
[TBL] [Abstract][Full Text] [Related]
40. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.
Paolucci S; Baldanti F; Maserati R; Castelli F; Suter F; Maggiolo F; Pan A; Gerna G
Antiviral Res; 2000 Feb; 45(2):101-14. PubMed ID: 10809019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
